AU Patent

AU2011278950C1 — c-Met modulator pharmaceutical compositions

Assigned to Exelixis Inc · Expires 2018-11-22 · 7y expired

What this patent protects

Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.

USPTO Abstract

Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: AU2011278950C1
Jurisdiction: AU
Classification: —
Expires: 2018-11-22
Drug substance claim: No
Drug product claim: No
Assignee: Exelixis Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.